Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world data on two-drug combo for hard-to-treat hodgkin lymphoma

NCT ID NCT07145125

Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 222 adults with Hodgkin lymphoma that had returned or not responded to first treatment. Researchers wanted to see how well the combination of brentuximab vedotin and bendamustine worked in everyday medical practice. They measured how long patients stayed free of progression and overall survival, along with side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
brentuximab vedotin and bendamustine
What this could lead to
If results are positive, this could confirm a useful treatment option for people whose Hodgkin lymphoma has come back or not responded to initial therapy.
What could go wrong
This is a real-world observational study, not a controlled trial, so results may be less reliable. The combination also has known side effects like nerve damage and low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

222 people

The number who actually took part.

Started

Feb 2025

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with relapsed or refractory HL, after at least one first line of treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with relapsed or refractory HL, after at least one first line of treatment * Aged 18 years and over * Having received at least one course of the Brenxutimab-Vedotin J1 and Bendamustine J1 + J2 combination Exclusion Criteria: * Minor patients * Pregnant women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed or refractory Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed or refractory Hodgkin lymphoma

Contacts and locations

Locations

  • CH de la Côte Basque, service Hématologie Clinique

    Bayonne, France

  • CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire

    Bordeaux, France

  • CHU de Caen, service Hématologie Clinique

    Caen, France

  • CHU de Toulouse, service Hématologie Clinique

    Toulouse, France

  • Institut Paoli Calmettes, service Hématologie Clinique

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.